Table 5.

Vascular function changes from placebo to antioxidant visits in patients with HFpEF grouped by medication usage

			FMD, ∆%			RH, ∆mL
Medication	Nonusers, n	Users, n	Nonuser	User	P Value	Nonuser	User	P Value
β-Blockers	9	7	2.3 ± 0.6	2.8 ± 1.2	0.29	6 ± 43	−32 ± 57	0.60
ACEi	13	3	1.7 ± 0.3	2.6 ± 0.7	0.61	9 ± 35	−81 ± 99	0.30
ARB	11	5	2.6 ± 0.7	2.1 ± 1.0	0.64	−25 ± 45	22 ± 49	0.53
Loop diuretics	4	12	2.0 ± 1.1	2.6 ± 0.7	0.73	−62 ± 15	5 ± 41	0.44
Aldosterone antagonists	4	12	2.6 ± 1.1	2.4 ± 0.7	0.87	−29 ± 22	−2 ± 46	0.73
Statins	7	9	1.4 ± 0.7	3.2 ± 0.8	0.13	−8 ± 43	−9 ± 50	0.99
Nitrates	14	2	2.5 ± 0.6	1.9 ± 2.3	0.73	−1 ± 38	63 ± 32	0.54

Values are means ± SE. ACEi, angiotensin-converting-enzyme inhibitor; ARB, angiotensin II receptor blocker; FMD, flow-mediated dilation change from placebo to antioxidant visits; RH, reactive hyperemia area under the curve change from placebo to antioxidant visits.